Death of Capsida trial studied to maintain viability of promising gene therapy

Researchers on Friday presented detailed investigations into a gene therapy death that last year sparked fear and uncertainty among scientists who believed they had approached powerful treatments for a long list of brain diseases.

The researchers did not conclude precisely what led to the patient’s death, but proposed experiments to test future treatments.

“What I want everyone to take away is: I think we’re starting to build a framework to test this,” said Nicholas Flytzanis, director of research and innovation at Capsida Biotherapeutics. “I think it can be tested, and I think this new specific risk is one that we can try to mitigate and predict in the future.”

Exclusive STAT+ story

STAT+

This article is reserved for STAT+ subscribers

Unlock this article – plus daily coverage and analysis of the biotech sector – by subscribing to STAT+.

Already have an account? Log in

See all packages

To read the rest of this story, subscribe to STAT+.

Subscribe

Gn Health

Logo